US2017281775A1PendingUtilityA1

Modifications of solid 3-sn-phosphoglycerides

58
Assignee: BIOMOLECULAR PRODUCTS INCPriority: Oct 11, 2001Filed: Nov 11, 2016Published: Oct 5, 2017
Est. expiryOct 11, 2021(expired)· nominal 20-yr term from priority
Inventors:David W. YesairWalter A. ShawStephen W. BurgessRobert Travis Mckee
A61P 43/00A61P 11/00A61K 47/24A61K 9/1274A61K 9/0014C12P 9/00C12P 13/06C12P 13/001C12P 7/6481
58
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods for hydrolyzing solid ungranulated lysophosphatidylcholine with phospholipase A 2 are provided. Also disclosed are methods for making a lipid matrix of lysophosphatidylcholine, monoglyceride and fatty acid, and lipid matrices of particular structure.

Claims

exact text as granted — not AI-modified
We claim: 
     
         1 . A drug delivery composition comprising
 a lipid matrix and a pharmaceutically acceptable carrier, wherein at least part of the lipid matrix is in a phase other than a lamellar phase, hexagonal phase or inverse hexagonal phase, wherein the lipid matrix comprises lysophosphoglyceride, monoglyceride and fatty acid, and wherein the molar ratio of lysophosphoglyceride:the sum of monoglyceride and fatty acid in the lipid matrix is between 1:3 and 1:12.   
     
     
         2 .- 8 . (canceled) 
     
     
         9 . The drug delivery composition of  claim 1 , wherein the molar ratio of lysophosphoglyceride:the sum of monoglyceride and fatty acid in the lipid matrix is between 1:5 and 1:6. 
     
     
         10 . The drug delivery composition of  claim 9 , wherein the lipid matrix has a lysophosphoglyceride:monoglyceride:fatty acid molar ratio between 1:4:2 and 1:2:4. 
     
     
         11 . The drug delivery composition of  claim 10 , wherein the lipid matrix has a lysophosphoglyceride:monoglyceride:fatty acid molar ratio selected from the group consisting of 1:4:2, 1:3:3 and 1:3:2. 
     
     
         12 . The drug delivery composition of  claim 1 , wherein the lysophosphoglyceride is lysophosphatidylcholine. 
     
     
         13 . The drug delivery composition  claim 1 , further comprising one or more water soluble or water insoluble pharmaceutical compounds. 
     
     
         14 .- 20 . (canceled) 
     
     
         21 . A nutritional supplement for the treatment of cystic fibrosis comprising an effective amount of the drug delivery composition of  claim 1 . 
     
     
         22 . A nutritional supplement comprising the drug delivery composition of  claim 1 .

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.